Prof. Lena Friberg, Ph.D.

Scientific Advisor


  • Co-founded Pharmetheus in 2012, advising in client projects and training Pharmetheus colleagues in pharmacometrics
  • Expertise includes development of pharmacokinetic-pharmacodynamic models of desired and adverse effects in therapeutic areas such as oncology, infectious diseases, and neuroscience
  • Experience as Professor of Pharmacometrics (2014-2021) and Pharmacokinetics and Pharmacodynamics (2021- ) at Uppsala University, Sweden, where she performs research and teaches in pharmacokinetics, pharmacodynamics, pharmacometrics, and drug development. Previously, she worked as Research Fellow and Associate Professor at Uppsala University, Sweden, and Postdoctoral Research Fellow at University of Queensland, Australia
  • M.Sc. in Pharmaceutical Sciences (1997) and Ph.D. in Pharmacokinetics and Drug Therapy (2003) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A framework for prediction of progression free survival based on modelling of sub-endpointsRituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarityApplication of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II studyPopulation Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients with Severe AsthmaRituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarityA PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients